The association of beta-fibrinogen 455 G/A gene polymorphism with left atrial thrombus and severe spontaneous echo contrast in atrial fibrillation;Atriyal fibrilasyonda beta-fibrinojen 455 G/A gen polimorfizmi ile sol atriyal trombüs ve ciddi spontan eko-kontrast arasindaki ilişki

Anadolu Kardiyoloji Dergisi

Volumn 10, Issue 3, 2010, Pages 209-215

  Bozdemir, Volkan ^a   Kirimli, Önder ^a   Akdeniz, Bahri ^a   Ülgenalp, Ayfer ^b   Aslan, Abdurrahman ^a   Kala, Veli ^a   Özel, Erdem ^a   Şenarslan, Ömer ^a   Badak, Özer ^a   Bariş, Nezihi ^a   Güeri, Sema ^a  

^a From Departments of Cardiology   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Atrial fibrillation; Beta fibrinogen; Gene polymorphism; Glycoprotein IIIa; Left atrium; Thrombus

Indexed keywords

ADENINE; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; GLYCOPROTEIN IIIA; GUANINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DETERMINATION; DNA POLYMORPHISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART LEFT ATRIUM; HUMAN; MALE; OBSERVATIONAL STUDY; RANK SUM TEST; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 77954346236     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2010.059     Document Type: Article

References (31)

1. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14:666-72.
2. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1: 526-9.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
4. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18:1098-100.
5. Atrial Fibrillation Investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-57.
6. Aschenberg W, Schluter M, Kremer P, Schröer E, Siglow V, Bleifeld W. Transesophageal two dimensional echocardiography for the detection of left atrial appendage thrombus. J Am Coll Cardiol 1986; 7:163-6.
7. Yang Y, Grosset DG, Li Q, Lees KR. Identification of echocardiographic "smoke" in a bench model with transcranial Doppler ultrasound. Stroke 2000; 31:907-14.
8. Rastegar R, Harnick DJ, Weidemann P, Fuster V, Coller B, Badimon JJ, et al. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol 2003; 41:603-10.
9. Stoddard MF, Singh P, Dawn B, Longaker RA. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J 2003; 145: 676-82.
10. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
11. Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
12. Koster T, Rosendaal FR, Reitsma PH, Van Der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost 1994; 71: 719-22.
13. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
14. De Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, et al. 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 1998; 18: 265-71.
15. Bi S, Wang D, Li G, Wen S, Pan S. Beta-fibrinogen promoter -455 G/A (HaeIII) polymorphism prediction of plasma fibrinogen but not of ischemic cerebrovascular disease. Chin Med Sci J 2004; 19:1-5.
16. Folsom AR, Aleksic N, Ahn C Boerwinkle E, Wu KK. β-Fibrinogen gene -455G/A polymorphism and coronary heart disease incidence: the Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol 2001; 11: 166-70.
17. Lam KS, Ma OC, Wat NM, Chan LC, Janus ED. Fibrinogen gene G/A-455 polymorphism in relation to fibrinogen concentrations and ischemic heart disease in Chinese patients with type II diabetes. Diabetologia 1999; 42: 1250-3.
18. Carter AM, Mansfield MW, Stickland MH, Grant PJ. Fibrinogen gene-455 G/A polymorphism and fibrinogen levels: risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care 1996; 19: 1265-8.
19. Martiskainen M, Pohjasvaara T, Mikkelsson J, MätyläR, Kunnas T, Laippala P. et al. Fibrinogen Gene Promoter -455 A Allele as a risk factor for lacunar stroke. Stroke 2003; 34: 886-91.
20. Doggen CJ, Bertina RM, Cats VM, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000; 110: 935-8.
21. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
22. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl (A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen beta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
23. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
24. Carabello, FK Chatterjeei, De Leon AC, Faxon DP, Freed MD et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 2006; 48; 1-148.
25. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo J Am Coll Cardiol 1994; 23: 961-9.
26. Li-Saw-Hee FL, Blann AD, Lip GY. Effect of blood pressure on the hypercoaguable state in chronic atrial fibrillation. Am J Cardiol 2000; 86: 795-7.
27. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble P- selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors. Circulation 2002; 106: 1962-7.
28. Weng X, Cloutier G, Genest J. Contribution of the -455G/A polymorphism at the beta-fibrinogen gene to erythrocyte aggregation in patients with coronary artery disease. Thromb Haemost 1999; 82: 1406-11.
29. Montgomery HE, Clarkson P, Nwose OM, Mikailidis DP, Jagroop IA, Dollery C, et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-455-A polymorphism of fibrinogen G-455-A polymorphism. Arterioscler Thromb Vasc Biol 1996; 16: 386-91.
30. Mosvowitz C, Mosvowitz HD, Jacobs LE, Meyerowitz CB, Podolsky LA, Kotler MN. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography. J Am Soc Echocardiogr 1993; 6: 107-14.
31. Fatkin D, Feneley M. Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: The relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Prog Cardiovasc Dis 1996; 39: 57-68.